- Home
- CXW vs MNKD Comparison
CXW vs MNKD Comparison
Compare CXW & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CXW
- MNKD
- Stock Information
- Founded
- CXW 1983
- MNKD 1991
- Country
- CXW United States
- MNKD United States
- Employees
- CXW N/A
- MNKD N/A
- Industry
- CXW Real Estate Investment Trusts
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- CXW Real Estate
- MNKD Health Care
- Exchange
- CXW Nasdaq
- MNKD Nasdaq
- Market Cap
- CXW 1.8B
- MNKD 1.7B
- IPO Year
- CXW 1997
- MNKD 2004
- Fundamental
- Price
- CXW $17.79
- MNKD $5.35
- Analyst Decision
- CXW Strong Buy
- MNKD Strong Buy
- Analyst Count
- CXW 2
- MNKD 6
- Target Price
- CXW $34.00
- MNKD $10.08
- AVG Volume (30 Days)
- CXW 1.3M
- MNKD 4.1M
- Earning Date
- CXW 11-05-2025
- MNKD 11-05-2025
- Dividend Yield
- CXW N/A
- MNKD N/A
- EPS Growth
- CXW 49.55
- MNKD 23.47
- EPS
- CXW 1.00
- MNKD 0.10
- Revenue
- CXW $2,086,522,000.00
- MNKD $313,787,000.00
- Revenue This Year
- CXW $9.24
- MNKD $14.78
- Revenue Next Year
- CXW $10.69
- MNKD $19.36
- P/E Ratio
- CXW $17.74
- MNKD $54.75
- Revenue Growth
- CXW 5.72
- MNKD 17.43
- 52 Week Low
- CXW $15.95
- MNKD $3.38
- 52 Week High
- CXW $23.85
- MNKD $7.07
- Technical
- Relative Strength Index (RSI)
- CXW 50.91
- MNKD 52.31
- Support Level
- CXW $15.95
- MNKD $4.93
- Resistance Level
- CXW $17.58
- MNKD $5.10
- Average True Range (ATR)
- CXW 0.74
- MNKD 0.22
- MACD
- CXW 0.12
- MNKD -0.02
- Stochastic Oscillator
- CXW 75.64
- MNKD 34.17
About CXW CoreCivic Inc.
CoreCivic Inc is an owner and operator of private prisons and detention centers in the United States. It operates in three segments: Safety, Community, and Properties. The Community segment owns and operates residential reentry centers. The Properties segment owns properties for lease to third parties and government agencies. The vast majority of the company's revenue comes from the CoreCivic Safety segment which consists of correctional and detention facilities that are owned, or controlled via a long-term lease, and managed by the company, as well as those correctional and detention facilities owned by third parties but managed by CoreCivic.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.